News
Seeing critical anatomy clearly during surgery can make all the difference. A fluorescence imaging technology developed by NIH inventors is moving closer to clinical testing through an exclusive patent license with Optosurgical, LLC. The license gives the Maryland-based surgical imaging company U.S
NIH inventors have developed a mutation-independent method to treat Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), other inherited retinal degenerations (IRDs), and age-related macular degeneration (AMD) using the FDA-approved small molecule, Halofantrine. NIH inventors found
Company Overview: AUTM is the nonprofit leader in efforts to educate, promote and inspire professionals – throughout their careers – to support the development of academic research that changes the world. AUTM’s community is comprised of more than 3,000 members who work in more than 800 universities
Age-related macular degeneration (AMD) affects approximately 200 million people worldwide and is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late-stage AMD would allow timely medical treatments, lifestyle interventions, more tailored